Loading…
Loading…
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies. Guangdong, China and Bagsværd, Denmark, 24 February 2026 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G).
Envestnet Asset Management Inc. bought a new stake in ProShares Ultra 20+ Year Treasury (NYSEARCA:UBT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 24,849 shares of the company's stock, valued at approximately $420,000. Envestnet Asset Management Inc. owned about 0.29%
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL's wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.
The stock market correction has raised fears of a recession, with the VIX index showing elevated volatility amid geopolitical and domestic uncertainties. The Trump administration's tariff initiatives and energy policies are causing market volatility but could potentially lower inflation and support a bond market rally. February's CPI data indicates receding inflation, suggesting the Fed may continue cutting short-term rates, which could boost economic growth and lower long-term rates.
The ProShares Ultra 20+ Year Treasury ETF (UBT) aims to deliver twice the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. UBT manages $116.30M, charges a 0.95% expense ratio, and leverages through swaps with a weighted average maturity of 25.90 years and duration of 17.58 years. Key drivers include monetary policy, inflation expectations, growth, geopolitical factors, and compounding from leverage resetting.
Long-duration Treasuries might be a buy, especially in a recession; consider ProShares Ultra 20+ Year Treasury ETF for leveraged exposure. UBT aims for 2x daily returns of the ICE U.S. Treasury 20+ Year Bond Index, using swaps for leverage. UBT's moderate leverage and lower expense ratio make it appealing compared to peers like Direxion Daily 20+ Year Treasury Bull 3X Shares.
Jon Wolfenbarger aims to help individual investors generate double-digit profits and beat the market in both bull and bear markets.
Treasuries are on a sharp rally fueled by bets that Fed rate hikes might be nearing an end. Investors could tap the opportune moment by going long on this instrument with the help of ETFs to make quick profits.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for UBT and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.